ABSTRACT
INTRODUCTION
Behavioral variant frontotemporal dementia (bvFTD) is characterized by a frontal lobe syndrome, resulting in profound behavioral and character changes, caused by a neurodegenerative disease [1;2] . However, many diseases of neurologic as well as psychiatric origin, may show a similar frontal lobe syndrome as seen in bvFTD [3] [4] [5] [6] [7] . Fortunately, recent research has made great progress in improving diagnostic biomarkers for the main neurodegenerative differential diagnoses (Alzheimer's disease (AD), Dementia with Lewy Bodies (DLB) and vascular dementia (VaD)), discriminating them more easily from bvFTD [8] [9] [10] [11] [12] . Nowadays, the main clinical dilemma is formed by the psychiatric differential diagnosis of bvFTD [6;13;14] . Differentiating between early bvFTD and primary psychiatric disorders is challenging due to the lack of a disease-specific biomarker, the absence of insight of the patients and the fact that bvFTD may present with psychiatric symptoms, fitting psychotic, compulsive or mood disorders [14] . Typical features like apathy, loss of initiative and economy of speech are seen in bvFTD as well as in negative symptoms in schizophrenia or mood disorders [15] [16] [17] [18] [19] [20] [21] [22] [23] . Similarly, in bipolar disorder, anxiety disorders, obsessive-compulsive disorder, autism or tic syndromes other behavioral disturbances like stereotypical or compulsive language and behavior or disinhibition occur as seen in bvFTD [24] [25] [26] [27] . Especially in the bvFTD subgroup with a C9orf72 mutation, psychiatric symptoms are often the presenting feature and a disease duration up to 20 years has been described, complicating differentiation from primary psychiatric causes [6;14;28;29] . As a consequence, up to 50% of bvFTD patients initially receives a psychiatric misdiagnosis [13] . Not much is known about misdiagnosis the other way around: bvFTD misdiagnosis in psychiatric disorders. With the publication of the Frontotemporal Dementia Consortium bvFTD criteria sensitivity has clearly improved, but specificity for bvFTD within a patient group with early manifestation of frontal lobe symptomatology, including psychiatric disorders, is unknown and might be limited [30] . The number of psychiatric patients fitting a bvFTD diagnosis according to the FTDC criteria has not been prospectively examined before. Since bvFTD is progressive and will eventually lead to death, whereas psychiatric disorders are treatable, every approach adding to the correct discrimination between the two is of paramount importance [14;31] . Our aim was to prospectively investigate the number of bvFTD misdiagnoses in other diagnoses, including primary psychiatric disorders, when applying the FTDC criteria in a memory clinic setting. Secondly, our aim was to examine whether the baseline characteristics differed between the patient group with a stable bvFTD diagnosis over time and the groups in which diagnosis was changed towards either a psychiatric diagnosis or a neurologic disorder. Especially characterizing the subgroup of patients with a psychiatric disorder mimicking bvFTD is of interest, since these patients are at risk for serious treatment delay.
METHODS

Participants
Study subjects were participants of the LOF-study (Late Onset Frontal lobe syndrome study, inclusion between April 2011 and June 2013), an observational prospective followup study including 137 subjects aged 45-75 years of which the study design and baseline characteristics were published previously [7;32] . The LOF study was designed to investigate which factors contribute to an early and accurate bvFTD diagnosis in a neuropsychiatric cohort. This present study focused on a subgroup with potential bvFTD misdiagnosis. For the present study subjects were drawn from the LOF-study when they had been referred to the memory clinic of the Alzheimer center (VU University Medical Center), were diagnosed with possible or probable bvFTD by a specialized neurologist after a standardized assessment and a follow-up diagnosis after two years was available. Patient who died during follow-up, were only included when there was no doubt on the underlying disease remained at the time of death.
Diagnostic assessment
All patients underwent standardized clinical assessment, consisting of behavioral and cognitive medical history, neurological exam, Mini-Mental State Examination (MMSE), frontal assessment battery (FAB), Montgomery-Asberg Depression Rating Scale (MADRS), Positive And Negative Symptom Scale (PANSS), and a neuropsychological test battery [32] . Informant based behavioral screening instruments were used to assess behavioral disturbances: the Frontal Behavioral Inventory (FBI), which is split in a positive (disinhibition) and a negative subscale (apathy and inertia), and the Stereotypy Rating Inventory (SRI).
All patients underwent an MRI-scan of the brain, visually assessed using the appropriate scales [33] [34] [35] . In case of normal MRI findings or doubt on the interpretation of the abnormalities being explanatory for the behavioral changes an [ 18 F]FDG-PET-scan was made. CSF was obtained with a lumbar puncture, performed according to standard medical procedure in the lateral position in the L3-L4, L4-L5 or L5-S1 intervertebral space by a 25-gauge needle and syringe. Reasons for not obtaining CSF included technical difficulties, use of oral anticoagulants, and patient refusal.
After clinical assessment a specialized neurologist (Y.P., N.P., P.S.) determined the most likely baseline diagnosis taking into account results from neuropsychological assessment, neuroimaging and CSF. A specialized psychiatrist (A.D, C.K., M.S.) also determined the most likely diagnosis at baseline, independent of the neurologist, taking into account all the available test results. In a subsequently held multidisciplinary meeting the neurologist could revise the diagnosis into the most likely baseline diagnosis after consulting the psychiatrist. Diagnoses were based upon the total workup described above and the NIA-AA guidelines for Alzheimer's disease, the NINDS-AIREN-criteria for vascular dementia, the international consensus diagnostic criteria for dementia with Lewy Bodies, the DSM-IV for psychiatric disorders and the FTDC criteria for bvFTD [10;12;30;36] .
This preliminary multidisciplinary diagnosis with the highest evidential ground possible at baseline was used as a clinical diagnosis in order to treat and guide the patient and caregivers. Patients were regularly followed in a clinical multidisciplinary setting. After 2 years of follow-up the clinical diagnosis was re-evaluated based on the clinical course, repeated MRI and repeated neuropsychological examination. For each patient a multidisciplinary meeting was held in which all available factors were carefully weighed. The final diagnosis after two years of follow-up was used as a gold standard.
For analysis the patients were grouped into ' bvFTD' , 'psychiatry' and 'other neurological disorders' based on their multidisciplinary follow-up diagnosis. In order to characterize the subjects in more detail a subdivision in possible and probable bvFTD was made. In case of a positive family history for dementia, patients were referred for clinical genetic counseling and optional genetic screening for MAPT, GRN, PSEN1 and APP genes. Taking into account the clinical overlap in C9orf72 cases and psychiatric disorders, C9orf72 genotyping was performed in all cases as part of this study [6;14;28;29] .
Medical ethical / informed consent
This study followed the Declaration of Helsinki on medical protocol and ethics and has been approved by the Medical Ethical Committee of the VU University medical center Amsterdam, the Netherlands. All subjects gave written informed consent for the use of their clinical data for research purposes.
Statistical analysis
Statistical analyses were performed using the IBM SPSS Statistics for Windows, version 22. Demographic baseline characteristics were compared between diagnostic patient groups (bvFTD diagnosis, psychiatric diagnosis or other neurological diagnoses (OND). Dichotomous variables were compared using the Pearson's χ 2 test. Non-parametric tests were used to investigate relationships between the diagnostic groups and the clinical scales (FBI, SRI, MMSE and FAB) because of the small sample size (Kruskal-Wallis). For significant findings, posthoc analyses were performed using Mann-Whitney U test with Bonferroni correction for multiple comparison. Results were considered to be statistically significant if p < 0.05 unless otherwise indicated.
RESULTS
A total of 35 patients received a possible bvFTD (n=5) or a probable bvFTD (n=30) diagnosis by the memory clinic neurologist at baseline and had follow-up information available. In 16 (45.5%) of the 35 patients, the bvFTD baseline diagnosis was changed. In two patients, the diagnosis was changed at baseline after psychiatric consultation and in 14 patients diagnosis was changed after two years of multidisciplinary follow-up by the neurologist and psychiatrist (Table 1 ). Ten patients (62.5% of the patients with a changed diagnosis, 28.5% of the total) eventually received a psychiatric diagnosis, of which mood disorders were the most common. Six patients (17%) received other neurologic diagnoses (OND), most commonly other neurodegenerative disorders like semantic dementia. The remaining 19 patients had a probable bvFTD diagnosis after two years based on the FTDC consensus criteria [30] . In all 5 cases with an initial possible bvFTD diagnosis made by the neurologist at baseline, the diagnosis changed towards a psychiatric diagnosis. No significant differences were found for age of onset (Kruskal-Wallis: H(2)=.07, p=.97), sex (Pearson's χ 2 (2) = 3.15, p=.21) and education (H(2)=.06, p=.97) between the three final diagnostic groups (stable bvFTD: 'FTD' , changed to psychiatry: 'psychiatry' and changed to other neurologic disorders: 'OND') ( Group differences between the three diagnostic groups after follow-up (bvFTD, psychiatric diagnoses and OND) were examined for the baseline results of the cognitive screening instruments and informant-based behavioral questionnaires. Results are depicted in Figure  1 . No significant differences were found for the MMSE (Kruskal- For the SRI, a significant group difference was found (Kruskal-Wallis: H(2)=6.41, p=.04) (Figure 1 ). Post-hoc analyses (with a Bonferroni corrected significance level of p <0.02) showed a significant higher score on the SRI in bvFTD patients compared to OND patients (Mann-Whitney U(1)=20.50, p=0.02). The other diagnostic groups did not differ significantly (FTD vs psychiatry: p=.25, psychiatry vs OND: p=.09) (Figure 1) . Table 3 shows the clinical descriptive characteristics of the patients and the clinical disease courses during follow-up. In most cases the clinical course of the disease and the evolution of symptoms combined with the presence or absence of neuroimaging progression, was very relevant for the final follow-up diagnosis. The patients in which the diagnosis was changed from bvFTD into a psychiatric diagnosis, complained about impaired memory function most frequently at baseline (n=7) or had no complaint at all (n=5), while their spouse or informant complained about more behavioral issues ( Table 3) . Part of these patients did not officially fulfill the criteria for a major psychiatric diagnosis. For instance, in these patients subthreshold mood disorders combined with impaired coping strategies due to personality (disorder) traits or severe relational disputes were found. Although some improvement was seen on the cognitive and behavioral screening instruments, in many of these patients the scores fluctuated or remained stable (two patients refused part of the follow-up assessment). The patients in which a probable bvFTD diagnosis was maintained almost all showed clear clinical progression, including the development of severe behavioral problems, the development of motor neuron disease in three patients, nursing home admission in four cases, prosopagnosia in one case and aphasia or semantic deficits in six patients (Table 3) . Almost half of the bvFTD patients were unable to complete the follow-up assessment due to serious disease progression. In one patient a progranulin mutation was found and in one patient a C9orf72 repeat expansion was found (Table 3 , case number 17 and number 35). In these two patients their final diagnosis was changed from probable bvFTD into definite bvFTD. All other subjects tested negative for C9orf72 mutation screening. More details on clinical reasoning and neuroimaging findings on an individual patient level are given in Table 3 . 
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DISCUSSION
Almost half of the bvFTD diagnoses made by the specialized memory clinic neurologist with the use of the FTDC criteria at baseline were changed, either after psychiatric consultation or after multidisciplinary neuropsychiatric follow-up. The most striking finding in this study is the number of bvFTD baseline misdiagnoses in actual psychiatric patients, since these patients have a curable or at least treatable disease. Especially a possible bvFTD diagnosis should be applied with caution and followed up carefully, since in our cohort all possible bvFTD baseline diagnoses were withdrawn during follow-up. We found six patients with other neurological disorders responsible for the behavioral disturbances initially labeled as bvFTD. Since the majority of these subjects had other neurodegenerative disorders, partly considered to be part of the same neurodegenerative spectrum (e.g. semantic dementia, corticobasal syndrome), these findings have less clinical impact because these patients are receiving proper and adequate memory clinic care from baseline on, even though their diagnosis changed during follow-up. However, patients with a psychiatric disorder would have missed adequate referral and treatment and their prognosis might have been worsened by diagnostic delay, had they not received clinical follow-up by a psychiatrist.
The recently developed FTDC criteria signify a great step forward, incorporating neuroimaging to determine the level of diagnostic certainty and increasing sensitivity for bvFTD diagnosis [30;37] . The need for cautious use of these new criteria with an increased sensitivity but also less restrictive exclusion features, especially in the psychiatric differential diagnosis, has been stressed by others as well [38] . Nonetheless, it is stated that a bvFTD diagnosis cannot be made in the presence of an explanatory psychiatric condition. The definition of 'dementia' as given in the DSM-IV does not capture the clinical FTD syndrome [15] . The DSM-5 criteria for 'cognitive disorders' have been adapted in order to include neurodegenerative disorders not presenting with memory decline as a first symptom, making them more fitting for bvFTD [16] . Still, the clinician must decide if the cognitive deficits are not primarily attributable to another mental disorder in which case no neurocognitive disorder may be diagnosed. Vice versa, before diagnosing a psychotic or mood disorder according to the DSM, one must exclude the possibility the symptoms may be caused by an organic or neurodegenerative disorder. This illustrates clearly that in clinical practice, in the absence of definitive biomarkers, the diagnostic dilemma "bvFTD or psychiatry" is not solved by simply applying the different sets of clinical consensus criteria.
The sensitivity of neuroimaging for bvFTD is about 50-63.5 % for MRI and about 81-90% for [ 18 F]FDG-PET within a memory clinic cohort [39] [40] [41] [42] . However, neuroimaging may reveal frontal atrophy or hypofrontality in psychiatric patients as well, compromising the specificity of these investigations [18;43-46] . This is emphasized by the considerable group of subjects in our cohort with initially a probable bvFTD diagnosis, based on clinical features and MRI or [
18 F]FDG-PET findings, in which the diagnosis was changed into a psychiatric disorder. The diagnostic change after follow-up was based upon clinical findings, increasingly suggesting a psychiatric origin of the complaints, as well as upon the absence of progression of neuroimaging abnormalities. So although neuroimaging is very valuable in a bvFTD diagnosis, the evaluation of further disease progression and imaging progression over time remains important. Notably, in all patients with an initial probable bvFTD diagnosis that was changed into a psychiatric diagnosis, the MRI findings were rated as normal and not suggestive of FTD, whereas the [ 18 F]FDG-PET was rated as abnormal. Therefore, especially the limited specificity of hypofrontality on [ 18 F]FDG-PET for bvFTD within a cohort including psychiatric disorders and not just dementia patients, should be prospectively studied in more detail, preferably with considerable follow-up or neuropathological confirmation.
Part of our cohort shows clinical similarities with patients labeled as the 'benign bvFTDphenocopy syndrome' by others [47] . This phenocopy-syndrome concerns patients, in whom clinical characteristics indistinguishable from possible bvFTD are found, but no functional decline nor neuroimaging abnormalities have been found. More evidence starts to emerge that atypical psychiatric disorders might be causing this so-called phenocopy syndrome and that psychiatric consultation might reveal treatable disorders, not always fitting the definition of a major psychiatric disease [14;48] . Interestingly, also part of our cohort with a psychiatric diagnosis did not officially fulfill the criteria for a major psychiatric diagnosis when strictly applied [48] . The subgroup of our cohort in which the diagnosis changed from possible bvFTD into a psychiatric disorder might fulfill this phenocopy syndrome definition. Nonetheless, our study shows a significant group of patients that do not fulfill the phenocopy description, since they do show hypometabolism on [
18 F]FDG-PET. A subgroup however, initially considered a probable bvFTD group, also had its diagnosis changed into an typical or atypical psychiatric disorder after follow-up, and are therefore not expected to show any more progress over time. This suggests that carefully screening patients psychiatrically is indicated in a larger group of subjects, and not just those fulfilling the 'phenocopy' definition. More prospective research is needed to further characterize this group in which screening is beneficial.
In our cohort none of the baseline characteristics differentiated between the three diagnostic groups. For clinical practice is it important to note that not only the informant based behavioral screening instruments, but also the widely used baseline MMSE and FAB did not differentiate between bvFTD and psychiatric disorders. This is in line with earlier findings: neuropsychological tests may help to identify mild to moderate bvFTD cases, but early bvFTD usually shows intact cognitive functions and the most often displayed executive dysfunction is also frequently seen in psychiatric disorders [20;49] . It must be noted that the examined cohort is part of a larger cohort focusing on early recognition of bvFTD [32] . Therefore all diagnoses were made in early staged disorders and the correct diagnosis may therefore be more difficult to discern from the differential diagnosis compared to more advanced cases.
Since we failed to identify clinically distinguishing features in the cognitive and behavioral screening, we would suggest consulting a psychiatrist in all possible and probable bvFTD cases in the early diagnostic phase and during follow-up.
Even though no statistically significant differences between the main diagnostic groups were found for sex, an interestingly higher number of subjects in whom diagnosis was changed from bvFTD towards a psychiatric diagnosis were male (9 out of 10). Also in the bvFTD phenocopy syndrome in previous research male gender predominated [47] . Further research should clarify if indeed males are more prone to be misdiagnosed as bvFTD in psychiatric disorders. This would be an interesting topic to study, as in women the opposite seems to hold: women showed to receive a psychiatric misdiagnosis in actual bvFTD more often compared to men [13] . Two cases revealed a pathologic mutation, responsible for the bvFTD syndrome. Their clinical pictures underline the known overlap between PGRN and C9orf72 repeat expansion on the one hand and psychiatric frontal syndromes on the other hand.
To our knowledge, this is the first prospective multidisciplinary study to investigate bvFTD misdiagnosis in primary psychiatric disorders. Our results are of great clinical relevance and strongly suggest incorporating a multidisciplinary approach when it comes to bvFTD early diagnosis and critically reviewing the diagnosis over time. Our data illustrate that the clinical profiles and in some cases the neuroimaging findings of the psychiatric patients in which a bvFTD misdiagnosis was made vividly mimic a bvFTD profile, considering the complaints mentioned by patients and their relatives. It strengthens our study that we blinded both the neurologist and the psychiatrist in the diagnostic process for each other's interpretations and results.
This study has several limitations. Our study was performed in a tertiary center. Therefore, our results cannot easily be extrapolated to a general population. Possibly, the number of misdiagnoses in our cohort is an underestimation of that in a general memory clinic due to the expertise available. On the other hand, it may be that more complex cases are referred to a tertiary center in the first place. Secondly, the study design shows that a consulting psychiatrist during follow-up is essential for identifying both bvFTD misdiagnoses and psychiatric diagnoses. Nonetheless, since the bvFTD differential diagnosis is complex and primary psychiatric disorders have no diagnostic gold standard and often have an atypical phenotype in the older population we strongly advise the multidisciplinary approach used in this study for future clinical practice. Especially in male patients, in patients with multiple psychiatric of psychological disorder traits and in patients merely fulfilling possible bvFTD, the FTCD criteria must be applied with caution and alternative diagnoses should be considered again during follow-up.
Furthermore, the used gold standard of two years follow-up may have been too short in some patients. It is hard to come by large numbers of suspected bvFTD subjects for prospective research, but we recommend future repetition of the study in a larger cohort, ideally with a full genetic screening or neuropathological confirmation to increase diagnostic certainty.
Our study results stress that not only the already known risk of making a psychiatric misdiagnosis in case of bvFTD is a pitfall to recognize [13] . Also, a bvFTD misdiagnosis in case of a psychiatric disorder could be an increasingly common scenario due to improved knowledge of bvFTD. Our findings suggest a limited specificity and a limited positive predictive value of the FTDC criteria. Further research on the factors discriminating bvFTD from psychiatric disorders is needed.
